HSP90AB1 and cancer: While inhibition of an essential, ubiquitously expressed protein warrants reservation, there is evidence to support that Hsp90 inhibitors exhibit a selectivity for cancer over normal cells: The active Hsp90 heteroprotein complex exhibits ∼200-fold higher affinity for ATP than the Hsp90 homodimer found in normal tissue, providing rationale for cancer selectivity (19).